As prostate cancer growth is dependent on androgens, androgen deprivation therapy (ADT), which includes surgical castration or medical therapy with gonadotropin-releasing hormone (GnRH) agonists or GnRH antagonists, is standard therapy for patients with metastatic prostate cancer recurrence after definitive therapy, or inoperable prostate cancer. Here, GNRH1 is linked to Familial prostate cancer.